Progress and prospects of gastric cancer treatment in the 21st century

Yonghu XU; Dazhi XU

doi:10.19401/j.cnki.1007-3639.2024.03.001

您当前的位置：

首页 >

文章列表页 >

Progress and prospects of gastric cancer treatment in the 21st century

Specialist' Commentary | 更新时间：2025-12-31

- Progress and prospects of gastric cancer treatment in the 21st century
- China Oncology Vol. 34, Issue 3, Pages: 239-249(2024)
- 作者机构：
  
  复旦大学附属肿瘤医院胃外1科，复旦大学上海医学院肿瘤学系，上海 200032
- 作者简介：
- 基金信息：
- DOI：10.19401/j.cnki.1007-3639.2024.03.001
  CLC： R
- Received：22 January 2024，
  
  Revised：2024-02-25，
  
  Published：30 March 2024
- 稿件说明：
移动端阅览
Yonghu XU, Dazhi XU. Progress and prospects of gastric cancer treatment in the 21st century[J]. China Oncology, 2024, 34(3): 239-249.
DOI：

Yonghu XU, Dazhi XU. Progress and prospects of gastric cancer treatment in the 21st century[J]. China Oncology, 2024, 34(3): 239-249. DOI： 10.19401/j.cnki.1007-3639.2024.03.001.

摘要

胃癌作为中国发病率及死亡率均位居前列的恶性肿瘤，具有异质性高、预后差等特点。进入21世纪，随着基因组学、腹腔镜微创技术、靶向治疗及免疫治疗的迅速发展，胃癌诊疗水平取得了长足进步。本文总结21世纪以来胃癌防治领域中的重要研究进展，并对未来进行展望，期待在胃癌早期筛查、诊断和精准治疗方面取得更大进步和突破，进一步提高患者的总生存率，将胃癌转变为可以控制的“慢性病”。

Abstract

Gastric cancer

a malignant tumor with high morbidity and mortality in China

has characteristics such as high heterogeneity and poor prognosis. With the advent of the 21st century

significant progress has been made in gastric cancer diagnosis and treatment due to the rapid development of genomics

laparoscopic minimally invasive techniques

targeted therapy and immunotherapy. This article summarized the important research progress in the field of gastric cancer prevention and treatment since the 21st century

and looked forward to the future. We hope to make greater progress and breakthroughs in early screening

diagnosis and precise treatment of gastric cancer

further improve the overall survival rate of patients

and transform gastric cancer into a controllable “chronic disease”.

关键词

Keywords

references

郑荣寿 , 张思维 , 孙可欣 , 等 . 2016年中国恶性肿瘤流行情况分析 [J ] . 中华肿瘤杂志 , 2023 , 45 ( 3 ): 212 - 220 .

ZHENG R S , ZHANG S W , SUN K X , et al . Cancer statistics in China, 2016 [J ] . Chin J Oncol , 2023 , 45 ( 3 ): 212 - 220 .

DENOIX P . Ongoing investigation in cancer centers [J ] . Bull Inst Natl Hyg , 1946 , 1 : 12 - 7 .

吴怀申 , 何雍毅 . 恶性肿瘤的TNM分类法 [J ] . 癌症 , 1999 ( 1 ): 104 - 105 .

WU H S , HE Y Y . TNM classification of malignant tumors [J ] . Chin J Cancer , 1999 ( 1 ): 104 - 105 .

RAMI-PORTA R . Future perspectives on the TNM Staging for lung cancer [J ] . Cancers (Basel) , 2021 , 13 ( 8 ): 1940.

日本胃癌学会 . 胃癌处理规约 [M ] . 1版. 东京 : 金原出版株式会社 , 1962 .

Japanese Gastric Cancer Association . Gastric cancer management protocol [M ] . 1 edition. Tokyo : Kanehara Publishing Co., LTD , 1962 .

日本胃癌学会 . 胃癌处理规约 [M ] . 14版. 东京 : 金原出版株式会社 , 2010 .

Japanese Gastric Cancer Association . Gastric cancer management protocol [M ] . 14 edition. Tokyo : Kanehara Publishing Co., LTD , 2010 .

CUSCHIERI A , WEEDEN S , FIELDING J , et al . Patient survival after D1 and D2 resections for gastric cancer: long-term results of the MRC randomized surgical trial. Surgical Co-operative Group [J ] . Br J Cancer , 1999 , 79 ( 9/10 ): 1522 - 1530 . DOI: 10.1038/sj.bjc.6690243 http://doi.org/10.1038/sj.bjc.6690243

BONENKAMP J J , HERMANS J , SASAKO M , et al . Extended lymph-node dissection for gastric cancer [J ] . N Engl J Med , 1999 , 340 ( 12 ): 908 - 914 . DOI: 10.1056/NEJM199903253401202 http://doi.org/10.1056/NEJM199903253401202 http://www.nejm.org/doi/abs/10.1056/NEJM199903253401202 http://www.nejm.org/doi/abs/10.1056/NEJM199903253401202

SONGUN I , PUTTER H , KRANENBARG E M , et al . Surgical treatment of gastric cancer: 15-year follow-up results of the randomised nationwide Dutch D1D2 trial [J ] . Lancet Oncol , 2010 , 11 ( 5 ): 439 - 449 . DOI: 10.1016/S1470-2045(10)70070-X http://doi.org/10.1016/S1470-2045(10)70070-X

SASAKO M , SANO T , YAMAMOTO S , et al . D2 lymphadenectomy alone or with para-aortic nodal dissection for gastric cancer [J ] . N Engl J Med , 2008 , 359 ( 5 ): 453 - 462 . DOI: 10.1056/NEJMoa0707035 http://doi.org/10.1056/NEJMoa0707035 http://www.nejm.org/doi/abs/10.1056/NEJMoa0707035 http://www.nejm.org/doi/abs/10.1056/NEJMoa0707035

MACDONALD J S , SMALLEY S R , BENEDETTI J , et al . Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction [J ] . N Engl J Med , 2001 , 345 ( 10 ): 725 - 730 . DOI: 10.1056/NEJMoa010187 http://doi.org/10.1056/NEJMoa010187 http://www.nejm.org/doi/abs/10.1056/NEJMoa010187 http://www.nejm.org/doi/abs/10.1056/NEJMoa010187

CUNNINGHAM D , ALLUM W H , STENNING S P , et al . Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer [J ] . N Engl J Med , 2006 , 355 ( 1 ): 11 - 20 . DOI: 10.1056/NEJMoa055531 http://doi.org/10.1056/NEJMoa055531 http://www.nejm.org/doi/abs/10.1056/NEJMoa055531 http://www.nejm.org/doi/abs/10.1056/NEJMoa055531

AL-BATRAN S E , HOMANN N , PAULIGK C , et al . Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2/3 trial [J ] . Lancet , 2019 , 393 ( 10184 ): 1948 - 1957 . DOI: 10.1016/S0140-6736(18)32557-1 http://doi.org/10.1016/S0140-6736(18)32557-1 https://linkinghub.elsevier.com/retrieve/pii/S0140673618325571 https://linkinghub.elsevier.com/retrieve/pii/S0140673618325571

KANG Y K , KIM H D , YOOK J H , et al . Neoadjuvant docetaxel, oxaliplatin, and s-1 plus surgery and adjuvant s-1 for resectable advanced gastric cancer: final survival outcomes of the randomized phase 3 PRODIGY trial [J ] . J Clin Oncol , 2023 , 41 ( 16 _suppl): 4067.

ZHANG X T , LIANG H , LI Z Y , et al . Perioperative or postoperative adjuvant oxaliplatin with S-1 versus adjuvant oxaliplatin with capecitabine in patients with locally advanced gastric or gastro-oesophageal junction adenocarcinoma undergoing D2 gastrectomy (RESOLVE): an open-label, superiority and non-inferiority, phase 3 randomised controlled trial [J ] . Lancet Oncol , 2021 , 22 ( 8 ): 1081 - 1092 . DOI: 10.1016/S1470-2045(21)00297-7 http://doi.org/10.1016/S1470-2045(21)00297-7 https://linkinghub.elsevier.com/retrieve/pii/S1470204521002977 https://linkinghub.elsevier.com/retrieve/pii/S1470204521002977

IWASAKI Y , TERASHIMA M , MIZUSAWA J , et al . Gastrectomy with or without neoadjuvant S-1 plus cisplatin for type 4 or large type 3 gastric cancer (JCOG0501): an open-label, phase 3, randomized controlled trial [J ] . Gastric Cancer , 2021 , 24 ( 2 ): 492 - 502 . DOI: 10.1007/s10120-020-01136-7 http://doi.org/10.1007/s10120-020-01136-7

SAKURAMOTO S , SASAKO M , YAMAGUCHI T , et al . Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine [J ] . N Engl J Med , 2007 , 357 ( 18 ): 1810 - 1820 . DOI: 10.1056/NEJMoa072252 http://doi.org/10.1056/NEJMoa072252 http://www.nejm.org/doi/abs/10.1056/NEJMoa072252 http://www.nejm.org/doi/abs/10.1056/NEJMoa072252

SASAKO M , SAKURAMOTO S , KATAI H , et al . Five-year outcomes of a randomized phase Ⅲ trial comparing adjuvant chemotherapy with S-1 versus surgery alone in stage Ⅱ or Ⅲ gastric cancer [J ] . J Clin Oncol , 2011 , 29 ( 33 ): 4387 - 4393 . DOI: 10.1200/JCO.2011.36.5908 http://doi.org/10.1200/JCO.2011.36.5908 https://ascopubs.org/doi/10.1200/JCO.2011.36.5908 https://ascopubs.org/doi/10.1200/JCO.2011.36.5908

KAKEJI Y , YOSHIDA K , KODERA Y , et al . Three-year outcomes of a randomized phase Ⅲ trial comparing adjuvant chemotherapy with S-1 plus docetaxel versus S-1 alone in stage Ⅲ gastric cancer: JACCRO GC-07 [J ] . Gastric Cancer , 2022 , 25 ( 1 ): 188 - 196 . DOI: 10.1007/s10120-021-01224-2 http://doi.org/10.1007/s10120-021-01224-2

BANG Y J , KIM Y W , YANG H K , et al . Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial [J ] . Lancet , 2012 , 379 ( 9813 ): 315 - 321 . DOI: 10.1016/S0140-6736(11)61873-4 http://doi.org/10.1016/S0140-6736(11)61873-4 https://linkinghub.elsevier.com/retrieve/pii/S0140673611618734 https://linkinghub.elsevier.com/retrieve/pii/S0140673611618734

LEE J , LIM D H , KIM S , et al . Phase Ⅲ trial comparing capecitabine plus cisplatin versus capecitabine plus cisplatin with concurrent capecitabine radiotherapy in completely resected gastric cancer with D2 lymph node dissection: the ARTIST trial [J ] . J Clin Oncol , 2012 , 30 ( 3 ): 268 - 273 .

PARK S H , LIM D H , SOHN T S , et al . A randomized phase Ⅲ trial comparing adjuvant single-agent S1, S-1 with oxaliplatin, and postoperative chemoradiation with S-1 and oxaliplatin in patients with node-positive gastric cancer after D2 resection: the ARTIST 2 trial [J ] . Ann Oncol , 2021 , 32 ( 3 ): 368 - 374 . DOI: 10.1016/j.annonc.2020.11.017 http://doi.org/10.1016/j.annonc.2020.11.017 https://linkinghub.elsevier.com/retrieve/pii/S0923753420431722 https://linkinghub.elsevier.com/retrieve/pii/S0923753420431722

KITANO S , ISO Y , MORIYAMA M , et al . Laparoscopy-assisted billroth I gastrectomy [J ] . Surg Laparosc Endosc , 1994 , 4 ( 2 ): 146 - 148 .

KIM H H , HAN S U , KIM M C , et al . Effect of laparoscopic distal gastrectomy vs open distal gastrectomy on long-term survival among patients with stage Ⅰ gastric cancer: the KLASS-01 randomized clinical trial [J ] . JAMA Oncol , 2019 , 5 ( 4 ): 506 - 513 . DOI: 10.1001/jamaoncol.2018.6727 http://doi.org/10.1001/jamaoncol.2018.6727 http://oncology.jamanetwork.com/article.aspx?doi=10.1001/jamaoncol.2018.6727 http://oncology.jamanetwork.com/article.aspx?doi=10.1001/jamaoncol.2018.6727

KATAI H , MIZUSAWA J , KATAYAMA H , et al . Survival outcomes after laparoscopy-assisted distal gastrectomy versus open distal gastrectomy with nodal dissection for clinical stage ⅠA or ⅠB gastric cancer (JCOG0912): a multicentre, non-inferiority, phase 3 randomised controlled trial [J ] . Lancet Gastroenterol Hepatol , 2020 , 5 ( 2 ): 142 - 151 .

ZENG Y K , YANG Z L , PENG J S , et al . Laparoscopy-assisted versus open distal gastrectomy for early gastric cancer: evidence from randomized and nonrandomized clinical trials [J ] . Ann Surg , 2012 , 256 ( 1 ): 39 - 52 . DOI: 10.1097/SLA.0b013e3182583e2e http://doi.org/10.1097/SLA.0b013e3182583e2e https://journals.lww.com/00000658-201207000-00008 https://journals.lww.com/00000658-201207000-00008

LIU F L , HUANG C M , XU Z K , et al . Morbidity and mortality of laparoscopic vs open total gastrectomy for clinical stage Ⅰ gastric cancer: the CLASS02 multicenter randomized clinical trial [J ] . JAMA Oncol , 2020 , 6 ( 10 ): 1590 - 1597 . DOI: 10.1001/jamaoncol.2020.3152 http://doi.org/10.1001/jamaoncol.2020.3152 https://jamanetwork.com/journals/jamaoncology/fullarticle/2769669 https://jamanetwork.com/journals/jamaoncology/fullarticle/2769669

YU J , HUANG C M , SUN Y H , et al . Effect of laparoscopic vs open distal gastrectomy on 3-year disease-free survival in patients with locally advanced gastric cancer: the CLASS-01 randomized clinical trial [J ] . JAMA , 2019 , 321 ( 20 ): 1983 - 1992 . DOI: 10.1001/jama.2019.5359 http://doi.org/10.1001/jama.2019.5359 http://jama.jamanetwork.com/article.aspx?doi=10.1001/jama.2019.5359 http://jama.jamanetwork.com/article.aspx?doi=10.1001/jama.2019.5359

HUANG C M , LIU H , HU Y F , et al . Laparoscopic vs open distal gastrectomy for locally advanced gastric cancer: five-year outcomes from the CLASS-01 randomized clinical trial [J ] . JAMA Surg , 2022 , 157 ( 1 ): 9 - 17 . DOI: 10.1001/jamasurg.2021.5104 http://doi.org/10.1001/jamasurg.2021.5104 https://jamanetwork.com/journals/jamasurgery/fullarticle/2785366 https://jamanetwork.com/journals/jamasurgery/fullarticle/2785366

HYUNG W J , YANG H K , PARK Y K , et al . Long-term outcomes of laparoscopic distal gastrectomy for locally advanced gastric cancer: the KLASS-02-RCT randomized clinical trial [J ] . J Clin Oncol , 2020 , 38 ( 28 ): 3304 - 3313 . DOI: 10.1200/JCO.20.01210 http://doi.org/10.1200/JCO.20.01210

ETOH T , OHYAMA T , SAKURAMOTO S , et al . Five-year survival outcomes of laparoscopy-assisted vs open distal gastrectomy for advanced gastric cancer: the JLSSG0901 randomized clinical trial [J ] . JAMA Surg , 2023 , 158 ( 5 ): 445 - 454 . DOI: 10.1001/jamasurg.2023.0096 http://doi.org/10.1001/jamasurg.2023.0096 https://jamanetwork.com/journals/jamasurgery/fullarticle/2802654 https://jamanetwork.com/journals/jamasurgery/fullarticle/2802654

PARK Y M , CHO E , KANG H Y , et al . The effectiveness and safety of endoscopic submucosal dissection compared with endoscopic mucosal resection for early gastric cancer: a systematic review and metaanalysis [J ] . Surg Endosc , 2011 , 25 ( 8 ): 2666 - 2677 . DOI: 10.1007/s00464-011-1627-z http://doi.org/10.1007/s00464-011-1627-z http://link.springer.com/10.1007/s00464-011-1627-z http://link.springer.com/10.1007/s00464-011-1627-z

FACCIORUSSO A , ANTONINO M , MASO M D , et al . Endoscopic submucosal dissection vs endoscopic mucosal resection for early gastric cancer: a meta-analysis [J ] . World J Gastrointest Endosc , 2014 , 6 ( 11 ): 555 - 563 . DOI: 10.4253/wjge.v6.i11.555 http://doi.org/10.4253/wjge.v6.i11.555 http://www.wjgnet.com/1948-5190/full/v6/i11/555.htm http://www.wjgnet.com/1948-5190/full/v6/i11/555.htm

JAPANESE GASTRIC CANCER ASSOCIATION . Japanese gastric cancer treatment guidelines 2010 (ver. 3) [J ] . Gastric Cancer , 2011 , 14 ( 2 ): 113 - 123 . DOI: 10.1007/s10120-011-0042-4 http://doi.org/10.1007/s10120-011-0042-4

JAPANESE GASTRIC CANCER ASSOCIATION . Japanese gastric cancer treatment guidelines 2014 (ver. 4) [J ] . Gastric Cancer , 2017 , 20 ( 1 ): 1 - 19 . DOI: 10.1007/s10120-016-0622-4 http://doi.org/10.1007/s10120-016-0622-4

HASUIKE N , ONO H , BOKU N , et al . A non-randomized confirmatory trial of an expanded indication for endoscopic submucosal dissection for intestinal-type gastric cancer (cT1a): the Japan Clinical Oncology Group study (JCOG0607) [J ] . Gastric Cancer , 2018 , 21 ( 1 ): 114 - 123 . DOI: 10.1007/s10120-017-0704-y http://doi.org/10.1007/s10120-017-0704-y

JAPANESE GASTRIC CANCER ASSOCIATION . Japanese gastric cancer treatment guidelines 2018 (5th edition) [J ] . Gastric Cancer , 2021 , 24 ( 1 ): 1 - 21 . DOI: 10.1007/s10120-020-01042-y http://doi.org/10.1007/s10120-020-01042-y

TAKIZAWA K , ONO H , HASUIKE N , et al . A nonrandomized, single-arm confirmatory trial of expanded endoscopic submucosal dissection indication for undifferentiated early gastric cancer: Japan Clinical Oncology Group study (JCOG1009/1010) [J ] . Gastric Cancer , 2021 , 24 ( 2 ): 479 - 491 . DOI: 10.1007/s10120-020-01134-9 http://doi.org/10.1007/s10120-020-01134-9

ASSOCIATION J G C . Japanese gastric cancer treatment guidelines 2021 (6th edition) [J ] . Gastric Cancer , 2023 , 26 ( 1 ): 1 - 25 . DOI: 10.1007/s10120-022-01331-8 http://doi.org/10.1007/s10120-022-01331-8

BANG Y J , VAN CUTSEM E , FEYEREISLOVA A , et al . Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial [J ] . Lancet , 2010 , 376 ( 9742 ): 687 - 697 . DOI: 10.1016/S0140-6736(10)61121-X http://doi.org/10.1016/S0140-6736(10)61121-X https://linkinghub.elsevier.com/retrieve/pii/S014067361061121X https://linkinghub.elsevier.com/retrieve/pii/S014067361061121X

HECHT J R , BANG Y J , QIN S K , et al . Lapatinib in combination with capecitabine plus oxaliplatin in human epidermal growth factor receptor 2-positive advanced or metastatic gastric, esophageal, or gastroesophageal adenocarcinoma: TRIO-013/LOGiC: a randomized phase Ⅲ trial [J ] . J Clin Oncol , 2016 , 34 ( 5 ): 443 - 451 .

SATOH T , XU R H , CHUNG H C , et al . Lapatinib plus paclitaxel versus paclitaxel alone in the second-line treatment of HER2-amplified advanced gastric cancer in Asian populations: TyTAN: a randomized, phase Ⅲ study [J ] . J Clin Oncol , 2014 , 32 ( 19 ): 2039 - 2049 . DOI: 10.1200/JCO.2013.53.6136 http://doi.org/10.1200/JCO.2013.53.6136 https://ascopubs.org/doi/10.1200/JCO.2013.53.6136 https://ascopubs.org/doi/10.1200/JCO.2013.53.6136

TABERNERO J , HOFF P M , SHEN L , et al . Pertuzumab plus trastuzumab and chemotherapy for HER2-positive metastatic gastric or gastro-oesophageal junction cancer (JACOB): final analysis of a double-blind, randomised, placebo-controlled phase 3 study [J ] . Lancet Oncol , 2018 , 19 ( 10 ): 1372 - 1384 . DOI: S1470-2045(18)30481-9 http://doi.org/S1470-2045(18)30481-9

THUSS-PATIENCE P C , SHAH M A , OHTSU A , et al . Trastuzumab emtansine versus taxane use for previously treated HER2-positive locally advanced or metastatic gastric or gastro-oesophageal junction adenocarcinoma (GATSBY): an international randomised, open-label, adaptive, phase 2/3 study [J ] . Lancet Oncol , 2017 , 18 ( 5 ): 640 - 653 . DOI: 10.1016/S1470-2045(17)30111-0 http://doi.org/10.1016/S1470-2045(17)30111-0 https://linkinghub.elsevier.com/retrieve/pii/S1470204517301110 https://linkinghub.elsevier.com/retrieve/pii/S1470204517301110

SHITARA K , BANG Y J , IWASA S , et al . Trastuzumab deruxtecan in previously treated HER2-positive gastric cancer [J ] . N Engl J Med , 2020 , 382 ( 25 ): 2419 - 2430 . DOI: 10.1056/NEJMoa2004413 http://doi.org/10.1056/NEJMoa2004413 http://www.nejm.org/doi/10.1056/NEJMoa2004413 http://www.nejm.org/doi/10.1056/NEJMoa2004413

VAN CUTSEM E , BARTOLOMEO M D , SMYTH E , et al . Trastuzumab deruxtecan in patients in the USA and Europe with HER2-positive advanced gastric or gastroesophageal junction cancer with disease progression on or after a trastuzumab-containing regimen (DESTINY-Gastric02): primary and updated analyses from a single-arm, phase 2 study [J ] . Lancet Oncol , 2023 , 24 ( 7 ): 744 - 756 . DOI: 10.1016/S1470-2045(23)00215-2 http://doi.org/10.1016/S1470-2045(23)00215-2

PENG Z , LIU T S , WEI J , et al . A phase Ⅱ study of efficacy and safety of RC48-ADC in patients with locally advanced or metastatic HER2-overexpressing gastric or gastroesophageal junction cancers [J ] . J Clin Oncol , 2020 , 38 ( 15 _suppl): 4560.

SHITARA K , LORDICK F , BANG Y J , et al . Zolbetuximab plus mFOLFOX6 in patients with CLDN18.2-positive, HER2-negative, untreated, locally advanced unresectable or metastatic gastric or gastro-oesophageal junction adenocarcinoma (SPOTLIGHT): a multicentre, randomised, double-blind, phase 3 trial [J ] . Lancet , 2023 , 401 ( 10389 ): 1655 - 1668 . DOI: 10.1016/S0140-6736(23)00620-7 http://doi.org/10.1016/S0140-6736(23)00620-7

SHAH M A , SHITARA K , AJANI J A , et al . Zolbetuximab plus CAPOX in CLDN18.2-positive gastric or gastroesophageal junction adenocarcinoma: the randomized, phase 3 GLOW trial [J ] . Nat Med , 2023 , 29 ( 8 ): 2133 - 2141 . DOI: 10.1038/s41591-023-02465-7 http://doi.org/10.1038/s41591-023-02465-7

KANG Y K , BOKU N , SATOH T , et al . Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial [J ] . Lancet , 2017 , 390 ( 10111 ): 2461 - 2471 . DOI: 10.1016/S0140-6736(17)31827-5 http://doi.org/10.1016/S0140-6736(17)31827-5 https://linkinghub.elsevier.com/retrieve/pii/S0140673617318275 https://linkinghub.elsevier.com/retrieve/pii/S0140673617318275

JANJIGIAN Y Y , SHITARA K , MOEHLER M , et al . First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial [J ] . Lancet , 2021 , 398 ( 10294 ): 27 - 40 . DOI: 10.1016/S0140-6736(21)00797-2 http://doi.org/10.1016/S0140-6736(21)00797-2

SHITARA K , ÖZGÜROĞLU M , BANG Y J , et al . Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial [J ] . Lancet , 2018 , 392 ( 10142 ): 123 - 133 . DOI: S0140-6736(18)31257-1 http://doi.org/S0140-6736(18)31257-1

BOKU N , RYU M H , KATO K , et al . Safety and efficacy of nivolumab in combination with S-1/capecitabine plus oxaliplatin in patients with previously untreated, unresectable, advanced, or recurrent gastric/gastroesophageal junction cancer: interim results of a randomized, phase Ⅱ trial (ATTRACTION-4) [J ] . Ann Oncol , 2019 , 30 ( 2 ): 250 - 258 . DOI: 10.1093/annonc/mdy540 http://doi.org/10.1093/annonc/mdy540 https://linkinghub.elsevier.com/retrieve/pii/S0923753419310361 https://linkinghub.elsevier.com/retrieve/pii/S0923753419310361

XU J , JIANG H , PAN Y , et al . LBA53 Sintilimab plus chemotherapy (chemo) versus chemo as first-line treatment for advanced gastric or gastroesophageal junction (G/GEJ) adenocarcinoma (ORIENT-16): First results of a randomized, double-blind, phase Ⅲ study [J ] . Ann Oncol , 2021 , 32 : S1331 .

MOEHLER M H , KATO K , ARKENAU H T , et al . Rationale 305: Phase 3 study of tislelizumab plus chemotherapy vs placebo plus chemotherapy as first-line treatment (1L) of advanced gastric or gastroesophageal junction adenocarcinoma (GC/GEJC) [J ] . J Clin Oncol , 2023 , 41 ( 4 _suppl): 286.

RHA S Y , OH D Y , YAÑEZ P , et al . Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for HER2-negative advanced gastric cancer (KEYNOTE-859): a multicentre, randomised, double-blind, phase 3 trial [J ] . Lancet Oncol , 2023 , 24 ( 11 ): 1181 - 1195 . DOI: 10.1016/S1470-2045(23)00515-6 http://doi.org/10.1016/S1470-2045(23)00515-6 https://linkinghub.elsevier.com/retrieve/pii/S1470204523005156 https://linkinghub.elsevier.com/retrieve/pii/S1470204523005156

JANJIGIAN Y Y , KAWAZOE A , YANEZ P E , et al . Pembrolizumab plus trastuzumab and chemotherapy for HER2+ metastatic gastric or gastroesophageal junction (G/GEJ) cancer: initial findings of the global phase 3 KEYNOTE-811 study [J ] . J Clin Oncol , 2021 , 39 ( 15 _suppl): 4013.

JANJIGIAN Y Y , KAWAZOE A , BAI Y , et al . Pembrolizumab plus trastuzumab and chemotherapy for HER2+ metastatic gastric or gastroesophageal junction (mG/GEJ) adenocarcinoma: survival results from the phase Ⅲ, randomized, double-blind, placebo-controlled KEYNOTE-811 study [J ] . Ann Oncol , 2023 , 34 : S851 -S852. DOI: 10.1016/j.annonc.2023.09.1424 http://doi.org/10.1016/j.annonc.2023.09.1424 https://linkinghub.elsevier.com/retrieve/pii/S0923753423022615 https://linkinghub.elsevier.com/retrieve/pii/S0923753423022615

YUAN S Q , NIE R C , JIN Y , et al . Perioperative PD-1 antibody toripalimab plus SOX or XELOX chemotherapy versus SOX or XELOX alone for locally advanced gastric or gastro-oesophageal junction cancer: results from a prospective, randomized, open-label, phase Ⅱ trial [J ] . J Clin Oncol , 2023 , 41 ( 16 _suppl): 4001.

DING X W , WANG X J , LI B , et al . PERSIST: A multicenter, randomized phase Ⅱ trial of perioperative oxaliplatin and S-1 (SOX) with or without sintilimab in resectable locally advanced gastric/gastroesophageal junction cancer (GC/GEJC) [J ] . J Clin Oncol , 2023 , 41 ( 4 _suppl): 364.

AL-BATRAN S E , LORENZEN S , THUSS-PATIENCE P C , et al . Surgical and pathological outcome, and pathological regression, in patients receiving perioperative atezolizumab in combination with FLOT chemotherapy versus FLOT alone for resectable esophagogastric adenocarcinoma: interim results from DANTE, a randomized, multicenter, phase Ⅱb trial of the FLOT-AIO German Gastric Cancer Group and Swiss SAKK [J ] . J Clin Oncol , 2022 , 40 ( 16 _sup pl): 4003.

THRIFT A P , WENKER T N , EL-SERAG H B . Global burden of gastric cancer: epidemiological trends, risk factors, screening and prevention [J ] . Nat Rev Clin Oncol , 2023 , 20 ( 5 ): 338 - 349 . DOI: 10.1038/s41571-023-00747-0 http://doi.org/10.1038/s41571-023-00747-0

CORDLE F . The use of epidemiology, scientific data, and regulatory authority to determine risk factors in cancers of some organs of the digestive system. 5. Stomach cancer [J ] . Regul Toxicol Pharmacol , 1986 , 6 ( 2 ): 171 - 180 . DOI: 10.1016/0273-2300(86)90032-2 http://doi.org/10.1016/0273-2300(86)90032-2 https://linkinghub.elsevier.com/retrieve/pii/0273230086900322 https://linkinghub.elsevier.com/retrieve/pii/0273230086900322

ASAKA M . A new approach for elimination of gastric cancer deaths in Japan [J ] . Int J Cancer , 2013 , 132 ( 6 ): 1272 - 1276 . DOI: 10.1002/ijc.27965 http://doi.org/10.1002/ijc.27965

ASAKA M , KATO M , SAKAMOTO N . Roadmap to eliminate gastric cancer with Helicobacter pylori eradication and consecutive surveillance in Japan [J ] . J Gastroenterol , 2014 , 49 ( 1 ): 1 - 8 . DOI: 10.1007/s00535-013-0897-8 http://doi.org/10.1007/s00535-013-0897-8

CHOI K S , SUH M . Screening for gastric cancer: the usefulness of endoscopy [J ] . Clin Endosc , 2014 , 47 ( 6 ): 490 - 496 . DOI: 10.5946/ce.2014.47.6.490 http://doi.org/10.5946/ce.2014.47.6.490

CHEN Z H , LIN L , WU C F , et al . Artificial intelligence for assisting cancer diagnosis and treatment in the era of precision medicine [J ] . Cancer Commun , 2021 , 41 ( 11 ): 1100 - 1115 . DOI: 10.1002/cac2.v41.11 http://doi.org/10.1002/cac2.v41.11 https://onlinelibrary.wiley.com/toc/25233548/41/11 https://onlinelibrary.wiley.com/toc/25233548/41/11

JUMPER J , EVANS R , PRITZEL A , et al . Highly accurate protein structure prediction with AlphaFold [J ] . Nature , 2021 , 596 ( 7873 ): 583 - 589 . DOI: 10.1038/s41586-021-03819-2 http://doi.org/10.1038/s41586-021-03819-2

Views

2767

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

Advanced progress in research and diagnosis of gastric cancer in 2022

Targeted therapy and immunotherapy combined with chemotherapy bring effective response to AFP positive colon cancer patients: a case report and literature review

Research status and progress of third-line treatment for metastatic colorectal cancer

Research progress and future perspectives of anticancer drug-induced interstitial lung disease/pneumonia in gastric cancer

Effectiveness and safety analysis of camrelizumab combined with chemotherapy and targeted therapy in patients with recurrent, metastatic, and treatment-naive advanced cervical cancer: a retrospective cohort study

Related Author

Jinling JIANG

Chenfei ZHOU

Chao WANG

Liqin ZHAO

Junwei WU

Jun ZHANG

LIU Miao

LI Jinze

Related Institution

Department of Oncology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine

Department of Oncology, Wuxi Branch of Ruijin Hospital, Shanghai Jiao Tong University School of Medicine

Department of Gastroenterology, the Fourth Hospital of Hebei Medical University

Department of Pathology, the Fourth Hospital of Hebei Medical University

Department of Oncology, The First Affiliated Hospital of Naval Medical University

AI问答

⁰